Cetuximab in Treating Patients With Advanced Solid Tumors
Information source: University of California, Davis
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: cetuximab (Biological); molecular diagnostic method (Genetic); immunologic technique (Other); laboratory biomarker analysis (Other)
Phase: Phase 1
Status: Completed
Sponsored by: University of California, Davis Official(s) and/or principal investigator(s): Angela Davies, MD, Study Chair, Affiliation: University of California, Davis
Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them.
PURPOSE: This phase I trial is studying the side effects and best dose of cetuximab in
treating patients with advanced solid tumors.
Clinical Details
Official title: A Phase I Study of the Safety and Tolerability of Four Doses of Cetuximab (C225) in Patients With Advanced Solid Tumors
Study design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Maximum tolerated dose of cetuximab
Secondary outcome: Safety and tolerability of cetuximabPotential predictors of response using correlative studies Correlation of efficacy of cetuximab with grade of skin rash Development of a detailed scale for assessing skin rash
Detailed description:
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of cetuximab in patients with advanced solid
tumors.
Secondary
- Evaluate the safety and tolerability of this drug in these patients.
- Develop a detailed scale for assessment of rash in these patients.
- Investigate potential predictors of response using correlative studies on patient
tissue, buccal mucosa, and blood samples.
- Obtain preliminary efficacy data and evaluate the relationship of efficacy to grade of
rash.
- Correlate downstream markers (e. g., pMAPK, pAKT, and Ki-67) and the presence of
epidermal growth factor receptor (EGFR) polymorphisms with clinical response and/or
survival.
- Examine the levels of downstream marker proteins in buccal cells obtained pre- and
post-treatment.
- Correlate basal p27 expression levels with response and/or survival.
- Determine if the presence of a K-RAS mutation influences response or survival outcome.
- Correlate the presence or absence of mutant K-RAS tumor DNA shed into patient plasma
with response and/or outcome.
- Correlate levels of cytokines and chemokines with rash and clinical response.
OUTLINE: This is an open-label, dose-escalation study.
Patients receive cetuximab IV over 90 minutes once weekly for 4 weeks. Treatment repeats
every 4 weeks for up to 12 courses in the absence of disease progression or unacceptable
toxicity.
Cohorts of 3-6 patients receive escalating doses of cetuximab until the maximum tolerated
dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2
of 6 patients experience dose-limiting toxicity. At least 6 patients are treated at the MTD.
Patients undergo blood and buccal mucosa collection at baseline and prior to courses 2 and 3
of treatment for molecular correlative studies. Archival tumor tissue specimens are also
used for molecular correlative studies. Immunologic correlative studies are performed using
patient blood samples.
After completion of study treatment, patients are followed periodically for survival.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Signed written informed consent
- Histologically or cytologically proven advanced solid tumors not curable by surgery,
radiation therapy or standard chemo-, immuno-, or hormonal therapy. A specific
primary cancer need not have been identified (i. e., unknown primary is eligible).
- Patients must have received at least one prior regimen (chemotherapy and/or
radiation) for metastatic disease. There is no limit to the number of prior
therapies.
- Any prior chemotherapy must have been completed at least 4 weeks prior to start of
study therapy. Previous radiation therapy must have been completed at least 2 weeks
prior to start of study therapy. All side effects of prior therapy must be resolved
prior to the start of study therapy.
- Patients with ZUBROD performance status 0-2 (see Appendix 1).
- Patients must have measurable disease or evaluable disease.
- Patients must have an estimated survival of at least 3 months.
- Patients with asymptomatic treated brain metastasis (surgical resection or
radiotherapy) may be included if they are neurologically stable and have been off
steroids for at least 4 weeks.
- Patients >/= 18 years of age.
- Patients of reproductive potential must agree to use an effective contraceptive
method while on treatment and for 3 months afterward as the effects of cetuximab on
the unborn fetus are unknown.
- Patients must have adequate hematologic function defined as: ANC >/= 1,500/mm3,
platelets >/= 100,000/mm3.
- Patients must have adequate hepatic function defined as SGOT = 3 x institutional
UNL and serum bilirubin = 2. 0 mg/dL.
- Patients must have adequate renal function defined as a serum creatinine level =
1. 6 mg/dL or a calculated creatinine clearance of >/= 40 ml/min.
Exclusion Criteria:
- Female patients cannot be pregnant or breastfeeding as the effects of cetuximab on
the unborn fetus are unknown. Documentation of a negative pregnancy test prior to
treatment is required for all women of reproductive potential.
- Uncontrolled intercurrent illness including but not limited to ongoing infection or
active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situation that would limit
compliance with study requirements.
- Patients with symptomatic brain metastasis or still requiring steroids.
- Patients who have received prior cetuximab therapy, prior therapy with any other drug
that targets the EGF receptor (including, but not limited to, Iressa, Tarceva,
Herceptin, CI1033, etc.), or prior therapy with a monoclonal antibody.
- Patients who have received prior chemotherapy within 4 weeks or radiation therapy
within 2 weeks prior to the start of study therapy.
- Prior hypersensitivity reaction to chimerized or murine monoclonal antibody therapy.
- Patients may not receive any other chemotherapy, radiation therapy, or biologic
therapy while on study.
Locations and Contacts
University of California Davis Cancer Center, Sacramento, California 95817, United States
Additional Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Starting date: December 2004
Last updated: March 25, 2010
|